Back to Results

Fulgent Genetics Inc (FLGT)

Featured in Small-Cap Stocks

Fulgent Genetics, Inc. is a healthcare company focused on clinical diagnostics and therapeutic development. Through its laboratory and testing services, it provides molecular diagnostics, genetic testing, and anatomic pathology services covering areas such as gastrointestinal, dermatopathology, urologic, breast, neuropathology, and hematopathology. The company also offers oncology-related tests and sequencer services connected to hereditary cancer, reproductive health, and other diseases. In addition, Fulgent is developing cancer-focused drug candidates through a nanoencapsulation and targeted therapy platform designed to improve the therapeutic profile of new and existing medicines. Its picture genetics platform combines gene probes, data analysis tools, adaptive learning software, and laboratory information systems to help identify health markers in DNA. The company serves physicians, patients, insurers, hospitals, laboratories, government entities, payors, and large corporations. Founded in 2011 and headquartered in El Monte, California, it traded on NASDAQ under the ticker FLGT as common stock.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-FLGT
$26.70
36.2% Upside
Undervalued
$15
-23.5% Downside
Overvalued
Fair
—
—
—
0.0%
July 30, 2026
-7.5x
0.5x
1.7x
556.9 M
-44.559 M
1.8%
61.8%
16.7
—
153.3%
Send a message
Valuation • Fair Value

Fulgent Genetics Inc (NASDAQ-FLGT) Fair Value by Valuation Model

Compare the primary fair value estimate for Fulgent Genetics Inc (NASDAQ-FLGT) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$26.70

Estimated upside of 36.2% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$31.44

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$30.03

Earnings power value estimate.

Comps Fair Value

$24.57

Comparable-company valuation reference.

Analyst Price Target

$15

Analysts imply downside of 23.5%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Fulgent Genetics Inc (NASDAQ-FLGT) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Fulgent Genetics Inc (NASDAQ-FLGT)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

320.3 M

Current operating scale indicator.

Revenue Forecast

352.2 M

Forward revenue estimate.

EBITDA

-77.195 M

Current operating profitability reference.

EBITDA Forecast

-55 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Fulgent Genetics Inc (NASDAQ-FLGT) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Fulgent Genetics Inc (NASDAQ-FLGT)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

1

Weak quality score that deserves closer review.

Beneish M-Score

-2.64

No elevated caution signal from this screen.

Altman Z-Score

16.7

Relatively strong balance-sheet zone.

FCF / Net Income

153.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Fulgent Genetics Inc (NASDAQ-FLGT). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Fulgent Genetics Inc (NASDAQ-FLGT)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 30, 2026

Days to Earnings

9

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Fulgent Genetics Inc (NASDAQ-FLGT), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Fulgent Genetics Inc (NASDAQ-FLGT) Stock Forecast & Technical Outlook

Review Fulgent Genetics Inc (NASDAQ-FLGT) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Fulgent Genetics Inc (NASDAQ-FLGT) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Fulgent Genetics Inc (NASDAQ-FLGT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Fulgent Genetics Inc (NASDAQ-FLGT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Fulgent Genetics Inc (NASDAQ-FLGT) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Fulgent Genetics Inc (NASDAQ-FLGT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Fulgent Genetics Inc (NASDAQ-FLGT)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Fulgent Genetics Inc (NASDAQ-FLGT) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

Fulgent Genetics Inc (NASDAQ-FLGT) Stock FAQ

Quick answers about Fulgent Genetics Inc (NASDAQ-FLGT) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$26.70
Estimated upside 36.2%
Valuation Rating
Undervalued
Estimated upside of 36.2%
Analyst Target
$15
Implied downside 23.5%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Fulgent Genetics Inc (NASDAQ-FLGT) is $26.70. This implies an estimated upside of 36.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 36.2% versus the current market price.

The available analyst price target for Fulgent Genetics Inc (NASDAQ-FLGT) is $15. The analyst target implies estimated downside of 23.5%.

The current financial health read for Fulgent Genetics Inc (NASDAQ-FLGT) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Fulgent Genetics Inc (NASDAQ-FLGT) is July 30, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Fulgent Genetics Inc (NASDAQ-FLGT) is -7.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Fulgent Genetics Inc is 556.9 M.

The current enterprise value listed for Fulgent Genetics Inc is -44.559 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Fulgent Genetics Inc is NASDAQ-FLGT, and the stock is listed on NASDAQ.

Fulgent Genetics Inc (NASDAQ-FLGT) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Fulgent Genetics Inc is 1.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Fulgent Genetics Inc is 61.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Providers & Services Stocks on NASDAQ View more

Guardant Health Inc (GH) Guardant Health Inc (GH)
Brightspring Health Services Inc (BTSG) Brightspring Health Services Inc (BTSG)
Brightspring Health Services Inc Unit (BTSGU) Brightspring Health Services Inc Unit (BTSGU)
The Ensign Group Inc (ENSG) The Ensign Group Inc (ENSG)
Henry Schein Inc (HSIC) Henry Schein Inc (HSIC)
Healthequity Inc (HQY) Healthequity Inc (HQY)
RadNet Inc (RDNT) RadNet Inc (RDNT)
Lifestance Health Group Inc (LFST) Lifestance Health Group Inc (LFST)
Alignment Healthcare LLC (ALHC) Alignment Healthcare LLC (ALHC)
Option Care Health Inc (OPCH) Option Care Health Inc (OPCH)
Privia Health Group Inc (PRVA) Privia Health Group Inc (PRVA)
Acadia Healthcare Company Inc (ACHC) Acadia Healthcare Company Inc (ACHC)
CorVel Corp (CRVL) CorVel Corp (CRVL)
Progyny Inc (PGNY) Progyny Inc (PGNY)
Clover Health Investments Corp (CLOV) Clover Health Investments Corp (CLOV)
Aveanna Healthcare Holdings Inc (AVAH) Aveanna Healthcare Holdings Inc (AVAH)
Surgery Partners Inc (SGRY) Surgery Partners Inc (SGRY)
Addus HomeCare Corporation (ADUS) Addus HomeCare Corporation (ADUS)
Astrana Health Inc (ASTH) Astrana Health Inc (ASTH)
NeoGenomics Inc (NEO) NeoGenomics Inc (NEO)
GeneDx Holdings Corp (WGS) GeneDx Holdings Corp (WGS)
InnovAge Holding Corp (INNV) InnovAge Holding Corp (INNV)
Adapthealth Corp (AHCO) Adapthealth Corp (AHCO)
Pennant Group Inc (PNTG) Pennant Group Inc (PNTG)